{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:12:46Z","timestamp":1779120766985,"version":"3.51.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Drug Authority"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended as first-line treatment for people living with HIV-1 (PLHIV) in Uganda. However, data on its safety profile in routine care remain limited. This study actively monitored adverse events (AEs) among PLHIV receiving DTG-based regimens, assessing factors associated with their occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective cohort study nested within a parent cohort from July 2021 to September 2022 across 3 Ugandan sites (urban, peri-urban, and rural). Adults on DTG\/lamivudine\/tenofovir (TLD), either transitioning from prior ART regimens or initiated on TLD as first-line therapy, were followed for 6 months. AEs were systematically captured using structured interviews and classified by the Medical Dictionary for Regulatory Activities System Organ Class. Univariable and multivariable logistic regression analyses identified predictors of AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 607 participants, 50 (8.2%) reported adverse events (AEs). Neuropsychiatric disorders were most common (2.5%), followed by cardiovascular (1.8%) and reproductive system disorders (1.5%). Other AEs, including gastrointestinal, eye, and skin disorders, were rare (&amp;lt;1%). In multivariable analysis, participants at site 3 and being single had significantly lower odds of AEs (aOR 0.04, 95% CI 0.00\u20130.29, P = .002), (aOR 0.45, 95% CI 0.22\u20130.92, P = .028). Prior exposure to Zidovudine-based regimens was associated with increased odds of AEs (aOR 3.33, 95% CI 1.43\u20137.75, P = .005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DTG-based ART regimens demonstrated a favorable safety profile, with AEs occurring infrequently and predominantly in neuropsychiatric, cardiovascular, and reproductive categories. Study site, Marital status and prior Zidovudine exposure were associated with AE risk, emphasizing the need for tailored monitoring, strengthened awareness in AE reporting and standardized pharmacovigilance across facilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag252","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:47:39Z","timestamp":1777376859000},"source":"Crossref","is-referenced-by-count":0,"title":["Adverse Events Among People Living With HIV Receiving Dolutegravir-Based Regimens: Findings From a 6-Month Active Pharmacovigilance Study in Uganda"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-4014","authenticated-orcid":false,"given":"Collins","family":"Ankunda","sequence":"first","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]},{"name":"Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6480-6753","authenticated-orcid":false,"given":"Sharon","family":"Namasambi","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curthbert","family":"Agolor","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-7903","authenticated-orcid":false,"given":"Susan","family":"Nakubulwa","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5566-2455","authenticated-orcid":false,"given":"Yvonne","family":"Karamagi","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-9911","authenticated-orcid":false,"given":"Ronald","family":"Mulebeke","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-7301","authenticated-orcid":false,"given":"Ivan","family":"Kasamba","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lukoma","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goefrey","family":"Kalungi","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jude","family":"Emunyu","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-5922","authenticated-orcid":false,"given":"Allan","family":"Serwanga","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1707-8035","authenticated-orcid":false,"given":"Sheila","family":"Ampaire","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Nakitto Kesi","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7961-9687","authenticated-orcid":false,"given":"Victoria","family":"Nambasa","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-5024","authenticated-orcid":false,"given":"Barbara","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre Uganda, Mildmay Uganda , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-4791","authenticated-orcid":false,"given":"Helen","family":"Byomire Ndagije","sequence":"additional","affiliation":[{"name":"Directorate of Product Safety, National Drug Authority , Kampala ,","place":["Uganda"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026051811514285000_ofag252-B1","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400\u2005mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026051811514285000_ofag252-B2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet (London, England)"},{"key":"2026051811514285000_ofag252-B3","author":"Ministry of Health, Republic of Uganda"},{"key":"2026051811514285000_ofag252-B4","author":"World Health Organization"},{"key":"2026051811514285000_ofag252-B5","volume-title":"Ministry of Health, Uganda. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Kampala, Uganda: Ministry of Health","year":"2020"},{"key":"2026051811514285000_ofag252-B6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/hiv.13761","article-title":"A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda","volume":"26","author":"Odongpiny","year":"2025","journal-title":"HIV Med"},{"key":"2026051811514285000_ofag252-B7","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2026051811514285000_ofag252-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026051811514285000_ofag252-B9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11096-024-01832-9","article-title":"Exploring the association of adverse drug reactions with medication adherence and quality of life among hypertensive patients: a cross-sectional study","volume":"47","author":"Insani","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"2026051811514285000_ofag252-B10","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1517\/14740338.2014.947260","article-title":"Adherence to therapy and adverse drug reactions: is there a link?","volume":"13","author":"Leporini","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2026051811514285000_ofag252-B11","author":"World Health Organization. Pharmacovigilance. 2025"},{"key":"2026051811514285000_ofag252-B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12981-024-00595-7","article-title":"Experiences of people living with HIV in low- and middle-income countries and their perspectives in self-management: a meta-synthesis","volume":"21","author":"Dadi","year":"2024","journal-title":"AIDS Res Ther"},{"key":"2026051811514285000_ofag252-B13","doi-asserted-by":"crossref","first-page":"ofae596","DOI":"10.1093\/ofid\/ofae596","article-title":"Evaluating the glycemic effects of dolutegravir and its predictors among people with human immunodeficiency virus in Uganda: a prospective cohort study","volume":"11","author":"Ankunda","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026051811514285000_ofag252-B14","volume-title":"Medical dictionary for regulatory activities (MedDRA)","author":"Therapeutic Goods Administration (TGA)","year":"2025"},{"key":"2026051811514285000_ofag252-B15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"2026051811514285000_ofag252-B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"2026051811514285000_ofag252-B17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12981-022-00442-7","article-title":"Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the immune suppression syndrome clinic of Mbarara regional referral hospital, Uganda: a mixed design study","volume":"19","author":"Namulindwa","year":"2022","journal-title":"AIDS Res Ther"},{"key":"2026051811514285000_ofag252-B18","volume-title":"HIV Antiretroviral therapy","author":"Kemnic","year":"2025"},{"key":"2026051811514285000_ofag252-B19","doi-asserted-by":"crossref","first-page":"108118","DOI":"10.1016\/j.ijid.2025.108118","article-title":"Increased risk of neuropsychiatric adverse events with dolutegravir-based antiretroviral therapy during pregnancy: findings from a prospective cohort study","volume":"161","author":"Namwase","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026051811514285000_ofag252-B20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(97)05376-8","article-title":"Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells","volume":"149","author":"Benbrik","year":"1997","journal-title":"J Neurol Sci"},{"key":"2026051811514285000_ofag252-B21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12981-023-00576-2","article-title":"Hypertension among persons living with HIV\/AIDS and its association with HIV-related health factors","volume":"21","author":"Denu","year":"2024","journal-title":"AIDS Res Ther"},{"key":"2026051811514285000_ofag252-B22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/hiv.13211","article-title":"Weight changes, metabolic syndrome, and all-cause mortality among Asian adults living with HIV","volume":"23","author":"Han","year":"2022","journal-title":"HIV Med"},{"key":"2026051811514285000_ofag252-B23","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/QAI.0000000000000267","article-title":"HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low- and middle-income country settings","volume":"67","author":"Narayan","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026051811514285000_ofag252-B24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s13104-016-2187-z","article-title":"A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe","volume":"9","author":"Magodoro","year":"2016","journal-title":"BMC Res Notes"},{"key":"2026051811514285000_ofag252-B25","volume-title":"Endotext","author":"Shindel","year":"2000"},{"key":"2026051811514285000_ofag252-B26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/sm2.25","article-title":"Erectile dysfunction among HIV patients undergoing highly active antiretroviral therapy: dyslipidemia as a main risk factor","volume":"2","author":"Romero-Velez","year":"2014","journal-title":"Sex Med"},{"key":"2026051811514285000_ofag252-B27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/QAD.0b013e328334444b","article-title":"Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors","volume":"24","author":"Moreno-P\u00e9rez","year":"2010","journal-title":"AIDS Lond Engl"},{"key":"2026051811514285000_ofag252-B28","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/jsm.12175","article-title":"Erectile dysfunction, testosterone deficiency, and risk of coronary heart disease in a cohort of men living with HIV in Belgium","volume":"10","author":"De Ryck","year":"2013","journal-title":"J Sex Med"},{"key":"2026051811514285000_ofag252-B29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/QAD.0000000000001348","article-title":"HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy","volume":"31","author":"Lach\u00e2tre","year":"2017","journal-title":"AIDS Lond Engl"},{"key":"2026051811514285000_ofag252-B30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/317457","article-title":"Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy","volume":"31","author":"Rietschel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026051811514285000_ofag252-B31","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/cells10051263","article-title":"Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data","volume":"10","author":"Otto","year":"2021","journal-title":"Cells"},{"key":"2026051811514285000_ofag252-B32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12889-020-8361-1","article-title":"The role of family factors in antiretroviral therapy (ART) adherence self-efficacy among HIV-infected adolescents in southern Uganda","volume":"20","author":"Nabunya","year":"2020","journal-title":"BMC Public Health"},{"key":"2026051811514285000_ofag252-B33","doi-asserted-by":"crossref","first-page":"569569","DOI":"10.3389\/fpubh.2021.569569","article-title":"Predictors of health seeking behaviours for common childhood illnesses in poor resource settings in Zambia, A community cross sectional study","volume":"9","author":"Apuleni","year":"2021","journal-title":"Front Public Health"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag252\/68190386\/ofag252.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag252\/68190386\/ofag252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag252\/68190386\/ofag252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:51:52Z","timestamp":1779119512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag252\/8665266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag252","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"ofag252"}}